Hospitalization length after myocardial infarction : risk-assessment-based time of hospital discharge vs. real life practice by Węgiel, Michał et al.
Journal of
Clinical Medicine
Article
Hospitalization Length after Myocardial Infarction:
Risk-Assessment-Based Time of Hospital Discharge
vs. Real Life Practice
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Abstract: According to guidelines, it is safe for low-risk patients with myocardial infarction (MI) to
be discharged within 72 h of hospitalization. However, results coming from registries show that
the hospital stay is often much longer in a real-life situation. Data on the length of the hospital stay
(LOS) of MI patients in Polish centers are lacking. We enrolled 212 consecutive patients with acute
MI. Low-risk patients were defined according to PAMI II criteria: age <70 years, left ventricular
ejection fraction (LVEF) >45%, no persistent ventricular arrhythmia, and no multi-vessel disease
(MVD). The median of the hospitalization length was eight days (Q1: 6; Q3: 9). In low-risk patients
(25%), the median of LOS was six days (Q1: 5; Q3: 7) (p < 0.001). In a logistic regression analysis
patients age, LVEF, ST-segment-elevation MI and the presence of MVD were independent predictors
of longer hospitals stay (≥8 days). During follow up, there were no significant differences in the
rates of clinical events between patients with shorter (<8 days) and longer (≥8 days) hospitalization.
In a real-life situation, the LOS, even in low-risk patients is much longer than recommended in
the guidelines.
Keywords: myocardial infarction; hospitalization length; predictors; follow up
1. Introduction
Risk stratification is crucial in the management of patients with acute myocardial infarction (MI).
It allows to implement tailored medical strategy and improve outcome. Previous studies are showing
the safety of discharge within 72 h of hospitalization in low-risk patients after an uncomplicated
MI [1–6]. Also, the European Society of Cardiology (ESC) guidelines on management of patients with
ST-segment elevation MI from 2017 recommend to consider a hospital discharge within 48–72 h in
low-risk individuals. On the other hand, data coming from registries are showing that the hospital stay
is often much longer, also with great variance between different regions in the world and individual
centers [7–9]. In a real-life scenario several factors, which are not included in typical risk scores, might
contribute to hospitalization length of patients with acute MI. Data about the length of hospital stay
(LOS) of MI patients in Polish centers are lacking. Thus, we sought to assess the LOS and factors
influencing hospitalization duration in patients with acute MI, hospitalized in a single center in Poland.
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2. Experimental Section
2.1. Study Population
The presented study is a retrospective analysis of consecutive patients diagnosed with acute
MI undergoing primary percutaneous coronary intervention (PCI), hospitalized between September
2016 and July 2017 in a single center. Both ST-segment elevation MI (STEMI) and non-ST-segment
elevation MI (NSTEMI) patients were included. During the study period, the total number of patients
hospitalized with acute MI was 261. Among these patients, eight (3%) did not undergo invasive
strategy with coronary angiography, six (2%) patients were referred to coronary artery bypass grafting
(CABG), and 35 (14%) were diagnosed with MI with non-obstructive coronary arteries (MINOCA).
These patients were excluded from analysis. Finally, 212 patients were enrolled (Figure 1).
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The study was approved by the Institutional Ethical Board of Jagiellonian University (project
identification number: 1072.6120.130.2017, date of approval: 28.09.2017). Patients baseline
characteristics and in-hospital course were analyzed according to risk and hospitalization length
categories. Low-risk patients were defined according to the criteria described in the second Primary
Angioplasty in Myocardial Infarction trial (PAMI II): age <70 years, left ventricular ejection fraction
(LVEF) >45%, no persistent ventricular arrhythmia, and no multi-vessel disease (MVD) [10]. In our
analysis, MVD was defined as at least two epicardial coronary arteries involved with atherosclerosis of
significant severity. Follow-up data were gathered from telephone interviews and medical records
in the hospital electronic database. Telephone interviews were conducted during a single telephone
call, between February 2018 and April 2018, solely by the authors. The telephone interview included
questions about urgent or scheduled hospitalizations, the cause of hospitalization, urgent or scheduled
cardiac procedures, myocardial infarction, and stroke. In the case of death, the cause of death
was recorded.
2.2. Statistical Analysis
Quantitative variables were described using means and standard deviation (for normal
distribution of data), or median with interquartile (Q) range (Q1 and Q3) (for non-normal distribution
of data). Quantitative data with normal distribution included: age and glomerular filtration rate
(GFR). Non-normal distribution of data presented hospitalization duration and LVEF. Categorical
variables were presented as percentages. The Mann–Whitney U test (for non-normal distribution
of data) or unpaired (two-sample) Student’s t-test (for normally distributed data) were applied for
continuous variables. The χ2 test was used for categorical (nominal and dichotomous) variables.
A multivariable logistic regression was constructed to identify independent predictors of longer
hospital stays (≥8 days, median of LOS in our study). All baseline variables were considered, and
forward selection with a probability value for covariates to enter the model was set at the 0.05 level.
Results are presented as odds ratios (OR) with an associated 95% confidence interval (CI). The rates of
all-cause and cardiovascular death, recurrent MI, and stroke were assessed during the hospital stay, and
follow-up and analyzed in relation to the risk and hospitalization length categories. Cardiovascular
mortality included death resulting from acute MI, heart failure, stroke, cardiovascular procedures, and
sudden cardiac death. Composite endpoint was defined as a combination of cardiovascular mortality,
non-fatal recurrent MI, and non-fatal stroke. Non-fatal MI and non-fatal stroke were defined as an
episode with survival until hospital discharge. Rates of events assessed during follow-up, included
also these which occurred during the index hospitalization. Survival was estimated by using the
Kaplan–Meier method, according to the risk and hospitalization length categories with the log-rank
test for the full follow-up time available. The level of statistical significance was set at alpha value
<0.05. All analyses were performed with SPSS Statistics 24 (IBM, Inc., Armonk, NY, USA).
3. Results
3.1. Patients’ Characteristics
Baseline characteristics are shown in Table 1. Most patients were male, and more frequent
clinical presentations was non-ST-elevation MI. During a hospital stay, 190 (90%) patients survived
until hospital discharge (Figure 1). The median hospitalization length in patients surviving MI was
eight days (Q1: 6; Q3: 9). The low-risk group consisted of 54 (25%) patients. In low-risk patients,
the median of LOS was six days (Q1: 5; Q3: 7), whereas in higher-risk individuals, the median of the
hospitalization length was eight days (Q1: 7; Q3: 10) (p < 0.001). Only one patient from the low-risk
group was discharged during first 72 h of hospitalization. Hospital discharge within four and five days
of hospitalization occurred at rates of five (9%) and 25 (46%) low-risk patients respectively. A histogram
of the lengths of hospital stays across the study population is presented in Figure 2.
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Table 1. Baseline and in-hospital clinical characteristics.
Patients Surviving until Hospital Discharge (n = 190) All Patients (n = 212)
LOS 8 <8 Days (92 Patients) LOS ≥8 Days (98 Patients) p-Value Higher-Risk (158 Patients) Low-Risk (54 Patients) p-Value
Baseline presentation
ST-elevation MI 1 (%) 22 37 0.03 33 24 0.24
Age (years) 64 ± 11 69 ± 12 0.003 71±11 57 ± 8 <0.001
Male gender (%) 71 64 0.36 63 76 0.097
Hypertension history (%) 82 82 1.0 79 78 0.85
Diabetes history (%) 29 41 0.13 41 24 0.03
COPD history 2 (%) 9 14 0.26 13 7 0.45
Smoking (%) 48 45 0.77 38 65 0.001
Stroke history (%) 8 11 0.46 11 2 0.048
MI history (%) 29 23 0.41 27 22 0.59
In-hospital characteristics
LVEF 3 (%) 55 (Q1: 45; Q3: 60) 45 (Q1: 38; Q3: 55) <0.001 45 (Q1: 37 Q3: 52) 56 (Q1: 50 Q3: 60) <0.001
LAD 4 culprit (%) 29 40 0.17 39 30 0.25
Multi-vessel disease (%) 23 48 <0.001 48 0 <0.001
Staged revascularization (%) 14 33 0.003 28 4 <0.001
Ventricular arrhythmia (%) 9 16 0.13 11 0 0.008
GFR 5 (mL/min/1.73 m2) 85 ± 28 77 ± 34 0.08 72 ± 33 92 ± 23 <0.001
RBC 6 transfusion (%) 2 4 0.68 4 2 0.68
Respiratory infections (%) 6 20 0.006 19 6 0.017
ACEI/ARB 7 (%) 88 88 1.0 78 91 0.04
B-blocker (%) 88 90 0.82 80 89 0.21
Loop diuretics (%) 24 42 0.009 47 9 <0.001
Aldosterone antagonists (%) 13 33 0.002 28 6 <0.001
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior descending artery; 5 glomerular filtration rate; 6 red blood cell;
7 angiotensin converting enzyme inhibitor, angiotensin receptor blocker, 8 length of hospital stay.
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By definition, low-risk patients were younger, with higher LVEF, and did not have MVD and
ventricular arrhythmias during hospital stay (Table 1). Low-risk patients also had a higher baseline
GFR, and less commonly had diabetes mellitus and history of stroke. During a hospital stay, those
patients less frequently had nosocomial respiratory tract infections, and less frequently required
loop diuretics or aldosterone inhibitors administration. On the other hand, low-risk patients were
more commonly treated with angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers. In Table 1 we also show the characteristics of patients according to LOS. Patients with
shorter hospitalization times (<8 days) were significantly younger, with higher LVEF, less commonly
had MVD or nosocomial infections, and less frequently required the administration of diuretics,
compared to patients with longer hospitalization times (≥8 days).
In Tables 2 and 3, we present patients’ characteristics in relation to the type of MI and the presence
of MVD. Patients presenting with MVD had significantly longer hospital stays compared to those
without MVD in angiography (Table 3).
Table 2. Baseline and in-hospital clinical characteristics in relation to the type of myocardial infarction.
ST-Elevation MI 1
(65 Patients)
Non-ST-Elevation MI
(147 Patients) p-Value
Baseline presentation
Age (years) 67 ± 13 67 ± 11 0.93
Male gender (%) 60 69 0.21
Hypertension history (%) 71 82 0.07
Diabetes history (%) 35 37 0.88
COPD history 2 (%) 11 12 1.0
Smoking (%) 48 43 0.65
Stroke history (%) 6 9 0.59
MI history 12 31 0.0 3
L w-risk (%) 20 28 0.24
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Table 2. Cont.
ST-Elevation MI 1
(65 Patients)
Non-ST-Elevation MI
(147 Patients) p-Value
In-hospital characteristics
Length of hospital stay (d) 8 (Q1: 7; Q3: 9) 7 (Q1: 6; Q3: 10) 0.19
LVEF 3 (%) 45 (Q1: 38; Q3: 55) 50 (Q1: 40; Q3: 55) 0.14
LAD 4 culprit (%) 45 33 0.12
Multi-vessel disease (%) 31 38 0.35
Staged revascularization (%) 20 22 0.86
Ventricular arrhythmia (%) 11 7 0.41
GFR 5 (mL/min/1.73 m2) 87 ± 35 73 ± 30 0.006
RBC 6 transfusion (%) 5 3 0.7
Respiratory infections (%) 15 16 1.0
ACEI/ARB 7 (%) 78 83 0.44
B-blocker (%) 80 84 0.56
Loop diuretics (%) 36 38 0.76
Aldosterone antagonists (%) 31 18 0.04
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior
descending artery; 5 glomerular filtration rate; 6 red blood cell; 7 angiotensin converting enzyme inhibitor,
angiotensin receptor blocker.
Table 3. Baseline and in-hospital clinical characteristics in relation to the presence of
multi-vessel diseases.
Multi-Vessel Disease
(76 Patients)
No Multi-Vessel Disease
(136 Patients) p-Value
Baseline presentation
ST-elevation MI 1 (%) 26 33 0.35
Age (years) 67 ± 10 67 ± 12 0.72
Male gender (%) 71 64 0.36
Hypertension history (%) 72 82 0.11
Diabetes history (%) 41 34 0.37
COPD history 2 (%) 8 13 0.27
Smoking (%) 46 44 0.89
Stroke history (%) 7 10 0.61
MI history (%) 24 26 0.74
Low-risk (%) 0 40 <0.001
In-hospital characteristics
Length of hospital stay (d) 8 (Q1: 7; Q3: 10) 7 (Q1: 5; Q3: 9) <0.001
LVEF 3 (%) 45 (Q1: 39; Q3: 55) 50 (Q1: 40; Q3: 58) 0.14
LAD 4 culprit (%) 34 38 0.66
Staged revascularization (%) 54 4 <0.001
Ventricular arrhythmia (%) 9 7 0.61
GFR 5 (mL/min/1.73 m2) 81 ± 35 76 ± 30 0.31
RBC 6 transfusion (%) 3 4 0.71
Respiratory infections (%) 16 15 1.0
ACEI/ARB 7 (%) 77 84 0.27
B-blocker (%) 83 82 1.0
Loop diuretics (%) 33 40 0.37
Aldosterone antagonists (%) 17 24 0.29
1 myocardial infarction; 2 chronic obstructive pulmonary disease; 3 left ventricular ejection fraction; 4 left anterior
descending artery; 5 glomerular filtration rate; 6 red blood cell; 7 angiotensin converting enzyme inhibitor,
angiotensin receptor blocker.
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In Table 4 we show logistic regression models for predicting longer hospital stay (≥8 days).
In a multivariate analysis patients’ age, LVEF, and the presence of ST-elevation MI and MVD were
independent predictors of hospitalization ≥8 days.
Table 4. Logistic regression model for predicting hospitalization lengths ≥8 days.
Univariate Analysis Multivariate Analysis
OR 7 95% CI 8 p-Value OR 95% CI p-Value
Baseline characteristics
Age (per one year increase) 1.04 1.01–1.07 0.004 1.04 1.01–1.07 0.016
Female gender 1.3 0.7–2.4 0.35
Arterial hypertension 1.0 0.48–2.1 0.98
Diabetes mellitus 1.7 0.91–3.0 0.1
History of MI 1 0.74 0.4–1.4 0.36
History of CABG 2 0.69 0.15–3.2 0.64
History of stroke 1.5 0.57–4.1 0.4
Smoking 0.89 0.5–1.6 0.69
Hyperlipidemia 0.87 0.47–1.6 0.64
COPD 3 1.75 0.7–4.4 0.23
Atrial fibrillation 2.1 0.97–4.7 0.06
Hemodialysis 1.9 0.34–10.7 0.46
In hospital characteristics
ST-elevation MI 2.09 1.1–4.0 0.025 2.3 1.1–4.7 0.02
LVEF 4 (per 1% increase) 0.95 0.93–0.98 0.001 0.97 0.94–0.99 0.016
Multi-vessel disease 3.1 1.7–5.8 <0.001 3.4 1.7–6.6 <0.001
Ventricular arrhythmia 2.2 0.7–7.5 0.2
RBC 5 transfusion 1.9 0.3–10.7 0.46
Pneumonia 3.7 1.4– 9.6 0.008
GFR 6 (per 1 mL/min/1.73 m2 increase) 0.9 0.98–1.0 0.09
Cox Snell R2 = 0.17; Nagelkerke R2 = 0.23; Hosmer Lemoshow test p = 0.33. 1 myocardial infarction; 2 coronary-artery
bypass grafting; 3 chronic obstructive pulmonary disease; 4 left ventricular ejection fraction; 5 red blood cell; 6
glomerular filtration rate; 7 odds ratio; 8 confidence interval.
3.2. Clinical Outcome
Follow-up was obtained in 200 (94%) patients. The median duration of follow-up was 10 (Q1: 6;
Q3: 13) months. Patients from the low-risk group had lower rates of all-cause mortality, cardiovascular
mortality, and combined endpoint during an in-hospital course and follow-up, compared to higher-risk
patients (Table 5).
There were no significant differences in rates of clinical events occurring in patients with shorter
(<8 days) and longer (≥8 days) hospitalization (Table 5). A Kaplan–Meier analysis showed higher
probabilities of general survival and survival without a combined endpoint in low-risk patients
compared to the higher-risk group. There were no significant differences in the Kaplan–Meier analysis
in relation to hospitalization length categories (Figure 3).
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Table 5. Rates of events occurring during the hospital stay and follow-up.
Patients Surviving until Hospital Discharge (n = 190) All Patients (n = 212)
LOS 2 <8 Days (92 Patients) LOS ≥8 Days (98 Patients) p-Value Higher-Risk (158 Patients) Low-Risk (54 Patients) p-Value
In hospital outcomes
All-cause mortality (%) - - - 14 0 0.001
Cardiovascular mortality (%) - - - 14 0 0.001
All recurrent MI 1 (%) 0 0 - 0 0 -
Non-fatal recurrent MI (%) 0 0 - 0 0 -
All stroke (%) 1 1 1.0 2 0 0.57
Non-fatal stroke (%) 1 1 1.0 1 0 1.0
Combined endpoint (%) 1 1 1.0 15 0 0.001
Long-term outcomes
All-cause mortality (%) 4 4 1.0 18 2 0.001
Cardiovascular mortality (%) 0 2 0.5 15 0 0.001
All recurrent MI (%) 11 7 0.45 8 9 0.77
Non-fatal recurrent MI (%) 11 6 0.3 7 9 0.56
All stroke (%) 2 2 1.0 4 0 0.34
Non-fatal stroke (%) 2 2 1.0 2 0 0.57
Combined endpoint (%) 12 10 0.82 24 9 0.02
1 myocardial infarction; 2 length of hospital stay.
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4. Discussion
Our most important finding is that in a real-life scenario, the LOS in low-risk patients appeared
to be much longer compare to that recomm nded in the guidelines. I the present study, only one
patient from the low-risk group w s discharged duri g the first 72 h of hospitalization.
Hospitalization length after MI has been sign ficantly declining over the years. In the 1970s,
an average LOS after MI was about 2–3 weeks [11,12]. Later o , studies showed the safety of a
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shortened hospital stay to be approximately seven days [13,14]. Several scores have been designed for
the risk assessment of patients hospitalized with acute MI [15–18]. One of the tools recommended for
risk evaluation by the current ESC guidelines on the management of patients with ST-segment elevation
MI are PAMI II criteria [19]. Guidelines recommend the consideration of a hospital discharge within
48–72 h in low-risk patients [19]. Several studies showed the safety of such an approach [1–4,20,21].
A study by Noman and colleagues on 2448 STEMI patients presented the feasibility of discharge
within two days after PCI in low-risk patients [3]. It is debatable as to whether keeping low-risk
patients in hospital for more than two days could cause an even greater reduction in mortality during
follow up. However, authors claim that in a propensity-matched analysis, a survival advantage of
earlier discharge was evident in that study [3]. Shorter hospital stays have been associated with a
lower risk of nosocomial infections, a faster return to the patient’s regular life, and a more favorable
cost–benefit ratio.
On the other hand, data coming from registries are showing that in a real-life situation, the hospital
stay is often much longer. There is also a large variance in hospitalization length between different
regions in the world [7–9]. A Canadian study from 1994 on over 11,000 patients showed a mean
LOS of 10 days [7]. Centers with lower volumes were associated with longer hospitalization lengths.
Importantly, the characteristics of patients and in-hospital courses explained only 12% of the variation
in LOS in that study. In the USA, an average hospitalization length after MI in the late 1990s was
approximately 4 to 6 days, whereas in Japan in 1998–2003, it was four weeks [8,9,22]. In the USA, the
length of hospitalization decreased from nine days in 1988, to six days in 1994. Invasive strategies
with early coronary angiography and PCI predicted a shorter hospital stay. However, demography
and baseline clinical characteristics explained only 6% of the variance in LOS. The type of center and
the occurrence of in-hospital complications explained an additional 27% of the variance. Authors
highlighted possible other factors, including economic and administrative issues, which might have
an impact on hospitalization length [8]. In a Japanese study from 2004, the mean LOS after MI was
approximately 31 days, with a slightly decreasing tendency from 32 to 30 days across the study period.
Clinical characteristics explained only 26% of the LOS variance. High volume hospitals and higher
occupation status were predictors of shorter hospitalization in that study [9].
In our analysis patients, clinical characteristics explained 23% of the variance in LOS, which
is consistent with previous studies. Also, in the above analyses, a large amount of unexplained
variance suggests presence of additional factors influencing LOS, which are not included in a typical
risk assessment.
It is worth mentioning that the PAMI II criteria of low-risk MI patients were established in
1998. The introduction of primary PCI, advancements in pharmacological treatment, and better
management of risk factors improved the survival of cardiovascular patients, but also led to a higher
age of patients presenting with first or recurrent MI. Nowadays, patients with MI are much older, and
with more comorbidities compared to those from 20 years ago, when the PAMI II criteria were designed.
Frailty, mental status and comorbidities may increase the risk of in-hospital complications, nosocomial
infections, and in the end, affect LOS [23]. Possibly, the PAMI II score, which consists of only four
parameters, might be not entirely usable for the current population of MI patients. Other issues
including staged PCI for complete revascularization, echocardiographic reassessment before discharge,
rehabilitation program, dietary and lifestyle education, and implementation of pharmacotherapy
might also prolong the hospital stay, but on the other hand, it may eventually improve the outcome.
Also, clinicians must often face logistic issues when discharging elderly and physically disabled
patients. In some centers, the transfer of patients from invasive cardiology units to more general
hospitals is a frequent practice, making a comparable analysis of LOS more challenging. Finally,
the financial systems in different countries promote more in-hospital treatment, and in other cases,
an outpatient care system. In presented study, the LOS was much longer compared to data coming
from the guidelines. Only one patient from the low-risk group was discharged during the first 72 h
of hospitalization. In our department, patients with myocardial infarction routinely start physical
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rehabilitation, are having pharmacotherapy up-titration, management of cardiovascular risk factors,
and sometimes psychological support during their hospital stay, which may explain the extended
hospitalization in this study.
Study limitations: The presented analysis is a retrospective registry, but it represents real-world
data, as consecutive patients were enrolled. Due to its retrospective character, several factors,
including biomarkers or additional parameters from echocardiographic examination, were not
available. The study is an observational analysis without randomization. The sample size and rates of
clinical events in this study are relatively small, which limits other variables that can be incorporated
into the regression analysis, and the final conclusions. A follow-up observation was not completed in
100% of patients, and it was relatively short.
5. Conclusions
In real-life situations, the LOS in low-risk patients appeared to be much longer than those
recommended in the guidelines. The patients’ characteristics associated with the risk assessment
explain the minority of variance in the hospitalization length, thus suggesting an impact of other
factors that is not included in typical risk scores.
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